EUVIMEDEUVIMED entdecken
Crossref

EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis

Victor Simmet, Astrid Lièvre, Emmanuelle Samalin, Hélène Senellart, Christelle De La Fouchardière, Christophe Borg, Antoine Adenis, David Malka, Véronique Guerin-Meyer, Ludovic Evesque, Meher Ben Abdelghani, Julien Edeline und 6 weitere

Clinical Colorectal Cancer · 2026-09

DOI: 10.1016/j.clcc.2026.09.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2026-09. Verfasst von Victor Simmet und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institut Cancérologie de l'Ouest, Angers, France. Electronic address: victor.simmet@ico.unicancer.fr. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Boehringer Ingelheim GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This phase II randomized trial evaluated the efficacy and safety of the combination of cetuximab and afatinib in chemorefractory metastatic colorectal cancer (mCRC). METHODS: We conducted a multicentre, open-label, randomized 2/1 noncomparative clinical trial in 75 patients with wild type (wt) RAS mCRC after chemotherapy failure. Patients (n = 51) received oral afatinib (40 mg/d) in combination with intravenous cetuximab (500 mg/m2 every 2 weeks) or cetuximab alone (n = 24) as an internal control arm. Crossover to afatinib was allowed after disease progression. The primary endpoint was the 6-month nonprogression rate with a minimal success rate of 30%. The prognostic value of circulating tumor cells (CTCs) was assessed in an ancillary analysis. RESULTS: In the combination arm, 9 patients (18%; 95% confidence interval [CI], 8-31), were progression-free at 6 months (primary endpoint not met). The objective response rate (ORR) was 26% (95% CI, 14-40). Median PFS and overall survival (OS) were 4.1 months (95% CI, 2.7-5.4) and 13.6 months (95% CI, 7.7-18.5) respectively. Thirty-seven patients (76%) in the combination arm and 16 patients (64%) in the control arm reported at least one severe (grade ≥ 3) toxicity. Two patients in the combination arm had grade 5 toxicity (sudden death and hypoglycemia). High baseline CTC levels and their decrease at day 14 were correlated to OS and ORR. CTC levels at day 14 were correlated to PFS. CONCLUSION: The combination of afatinib and cetuximab was ineffective in treating chemorefractory wtRAS mCRC, and associated with high toxicity.

Schlagwörter

Stichwörter der Autor:innen

Circulating tumor cellsEGFR inhibitorPrognosistyrosine kinase inhibitor

Autor:innen und Institutionen

  • Institut Cancérologie de l'Ouest, Angers, France. Electronic address: victor.simmet@ico.unicancer.fr.
  • CHU Rennes, Rennes, France.
  • ICM, Val d'Aurelle, Université Montpellier, Montpellier, France.
  • Institut Cancérologie de l'Ouest, Saint-Herblain, France.
  • Institut Paoli Calmettes, Marseille, France.
  • Hôpital Nord Franche-Comté, University Hospital of Besançon, Besançon, France.

Förderung

  • Boehringer Ingelheim GmbH

Zitieren

APA

Simmet, V., Lièvre, A., Samalin, E., Senellart, H., De La Fouchardière, C., Borg, C., Adenis, A., Malka, D., Guerin-Meyer, V., Evesque, L., Abdelghani, M. B., Edeline, J., André, T., Ghiringhelli, F., Raoul, J. L., Monard, L., Gourgou, S., & Bennouna, J. (2026). EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2026.09.001

Vancouver

Simmet V, Lièvre A, Samalin E, Senellart H, De La Fouchardière C, Borg C, et al. EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis. Clinical Colorectal Cancer. 2026. doi:10.1016/j.clcc.2026.09.001

BibTeX
@article{Simmet2026,
  author = {Simmet, Victor and Lièvre, Astrid and Samalin, Emmanuelle and Senellart, Hélène and De La Fouchardière, Christelle and Borg, Christophe and Adenis, Antoine and Malka, David and Guerin-Meyer, Véronique and Evesque, Ludovic and Abdelghani, Meher Ben and Edeline, Julien and André, Thierry and Ghiringhelli, Francois and Raoul, Jean-Luc and Monard, Laure and Gourgou, Sophie and Bennouna, Jaafar},
  title = {EGFR Targeting With Afatinib and Cetuximab Versus Cetuximab Alone in Chemorefractory Wild-type RAS Metastatic Colorectal Cancer: A Randomized Phase II Study With Circulating Tumor Cell Analysis},
  journal = {Clinical Colorectal Cancer},
  year = {2026},
  doi = {10.1016/j.clcc.2026.09.001}
}
Kostenlos starten →